180 related articles for article (PubMed ID: 16127461)
1. Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms.
Fütterer A; Campanero MR; Leonardo E; Criado LM; Flores JM; Hernández JM; San Miguel JF; Martínez-A C
J Clin Invest; 2005 Sep; 115(9):2351-62. PubMed ID: 16127461
[TBL] [Abstract][Full Text] [Related]
2. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG).
Bench AJ; Nacheva EP; Hood TL; Holden JL; French L; Swanton S; Champion KM; Li J; Whittaker P; Stavrides G; Hunt AR; Huntly BJ; Campbell LJ; Bentley DR; Deloukas P; Green AR
Oncogene; 2000 Aug; 19(34):3902-13. PubMed ID: 10952764
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of del(20q) in patients with hematological malignancies.
Brezinová J; Zemanová Z; Ransdorfová S; Sindelárová L; Sisková M; Neuwirtová R; Cermák J; Michalová K
Cancer Genet Cytogenet; 2005 Jul; 160(2):188-92. PubMed ID: 15993278
[TBL] [Abstract][Full Text] [Related]
4. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
Huh J; Tiu RV; Gondek LP; O'Keefe CL; Jasek M; Makishima H; Jankowska AM; Jiang Y; Verma A; Theil KS; McDevitt MA; Maciejewski JP
Genes Chromosomes Cancer; 2010 Apr; 49(4):390-9. PubMed ID: 20095039
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.
Douet-Guilbert N; Basinko A; Morel F; Le Bris MJ; Ugo V; Morice P; Berthou C; De Braekeleer M
Ann Hematol; 2008 Jul; 87(7):537-44. PubMed ID: 18350294
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.
Santana-Davila R; Holtan SG; Dewald GW; Ketterling RP; Knudson RA; Hanson CA; Steensma DP; Tefferi A
Leuk Res; 2008 Mar; 32(3):407-11. PubMed ID: 17707907
[TBL] [Abstract][Full Text] [Related]
7. Dido disruption leads to centrosome amplification and mitotic checkpoint defects compromising chromosome stability.
Trachana V; van Wely KH; Guerrero AA; Fütterer A; Martínez-A C
Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2691-6. PubMed ID: 17299043
[TBL] [Abstract][Full Text] [Related]
8. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
9. Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML.
Gandini D; De Angeli C; Aguiari G; Manzati E; Lanza F; Pandolfi PP; Cuneo A; Castoldi GL; del Senno L
Leukemia; 2002 May; 16(5):886-93. PubMed ID: 11986951
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders.
Campbell LJ; Garson OM
Leukemia; 1994 Jan; 8(1):67-71. PubMed ID: 8289501
[TBL] [Abstract][Full Text] [Related]
11. Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells.
MacGrogan D; Kalakonda N; Alvarez S; Scandura JM; Boccuni P; Johansson B; Nimer SD
Genes Chromosomes Cancer; 2004 Nov; 41(3):203-13. PubMed ID: 15334543
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathogenesis of MDS.
Look AT
Hematology Am Soc Hematol Educ Program; 2005; ():156-60. PubMed ID: 16304374
[TBL] [Abstract][Full Text] [Related]
13. Death inducer obliterator protein 1 in the context of DNA regulation. Sequence analyses of distant homologues point to a novel functional role.
Rojas AM; Sanchez-Pulido L; Fütterer A; van Wely KH; Martinez-A C; Valencia A
FEBS J; 2005 Jul; 272(14):3505-11. PubMed ID: 16008551
[TBL] [Abstract][Full Text] [Related]
14. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies.
Bench AJ; Li J; Huntly BJ; Delabesse E; Fourouclas N; Hunt AR; Deloukas P; Green AR
Br J Haematol; 2004 Dec; 127(5):509-18. PubMed ID: 15566354
[TBL] [Abstract][Full Text] [Related]
16. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes.
Asimakopoulos FA; White NJ; Nacheva E; Green AR
Blood; 1994 Nov; 84(9):3086-94. PubMed ID: 7949181
[TBL] [Abstract][Full Text] [Related]
18. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
[TBL] [Abstract][Full Text] [Related]
19. Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11.
Buijs A; Sherr S; van Baal S; van Bezouw S; van der Plas D; Geurts van Kessel A; Riegman P; Lekanne Deprez R; Zwarthoff E; Hagemeijer A
Oncogene; 1995 Apr; 10(8):1511-9. PubMed ID: 7731705
[TBL] [Abstract][Full Text] [Related]
20. Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation.
Stoner SA; Yan M; Liu KTH; Arimoto KI; Shima T; Wang HY; Johnson DT; Bejar R; Jamieson C; Guan KL; Zhang DE
Blood; 2019 Nov; 134(20):1730-1744. PubMed ID: 31434702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
